3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Melanoma
2
Carcinoma, Renal Cell
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Breast Neoplasms
1
Interventions
Blood Specimen Collection
3
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
3
Surveys and Questionnaires
2
Prednisone
2
Positron-Emission Tomography
2
Magnetic Resonance Imaging
2
Injections
2
vistusertib
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
pembrolizumab
1
lortalamine
1
ioflupane
1
gossypol acetic acid
1
carbon-11 acetate
1
abiraterone
1
Waiting Lists
1
Urine Specimen Collection
1
Urination
1
Transcutaneous Electric Nerve Stimulation
1
Therapeutics
1
Specimen Handling
1
Referral and Consultation
1
Prostatectomy
1
Preoperative Exercise
1
Positron Emission Tomography Computed Tomography
1
Pluvicto
1
Observation
1
Music Therapy
1
Multiparametric Magnetic Resonance Imaging
1
Mitomycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
Interleukin-15
×
Genitourinary
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled